Phoenix PharmaLabs’ Lead Compound, PPL-138, Offers Promise as PTSD/AUD Treatment
WOODS CROSS, Utah--(BUSINESS WIRE)--Phoenix PharmaLabs, Inc. (https://phoenixpharmalabs.com), a private company developing potent, non-addictive treatments for pain and addiction, today announced the receipt of an $8.7 million grant from the National Institute on Drug Abuse (NIDA). The primary focus of the grant is to study the company’s lead compound, PPL-138, for the treatment of cocaine use disorder (CUD). The grant has been awarded as part of NIH’s HEAL – The Helping to End Addiction Long-Term® Initiative. This trans-agency effort is working to speed scientific solutions to stem the national public health crisis.
Phoenix PharmaLabs, Inc. (https://phoenixpharmalabs.com), a private company developing two non-addictive opioid compounds to treat acute and chronic pain, today announced it has completed a second successful round of financing raising $1.07 million via the Netcapital (https://netcapital.com) equity funding portal. Like its earlier 2019 Netcapital offering, this raise, which was carried out under Reg CF was also oversubscribed.
SALT LAKE CITY--(BUSINESS WIRE)--Phoenix PharmaLabs, a privately-held pre-clinical drug discovery company dedicated to the development of potent, non-addictive treatments for pain and addiction, today announced it has completed a license agreement with the University of Bath in England for exclusive rights to a portfolio of 25 NOP (Nociceptin) compounds. The specific terms of the license agreement were not disclosed.
SALT LAKE CITY--(BUSINESS WIRE)--Phoenix PharmaLabs, a privately held, preclinical drug company dedicated to developing potent, non-addictive treatments for pain and opioid and cocaine addictions, announced it has launched its second offering campaign on the Netcapital platform: https://netcapital.com/companies/phoenix.
BOSTON, May 13, 2020 (GLOBE NEWSWIRE) -- Phoenix Tissue Repair, Inc. (PTR), an affiliate company of BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced updates to its ongoing Phase 1/2 study of PTR-01 (BridgeBio designation BBP-589), an intravenously-administered recombinant collagen 7 protein replacement therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB). Cohorts 1 – 3 have completed treatment at escalating dose levels, and an additional fourth cohort to evaluate higher dosing of PTR-01 has begun enrolling patients.